Repligen Corporation Common Stock vs Solaredge Technologies Inc — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Solaredge Technologies Inc trades at $30.06 (market cap $2.00B). The key difference: Repligen Corporation Common Stock is far larger — about 5.6× Solaredge Technologies Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Solaredge Technologies Inc for 34 Days on average.
| RGEN | SEDG | |
|---|---|---|
Market Cap | $11.14B | $2.00B |
Volume | 1,259,263 | 2,563,287 |
Sector | Health | Energy |
52-Week High | $194.57 | $78.51 |
52-Week Low | $102.87 | $28.47 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $11.02B | $1.86B |
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SolarEdge Technologies (SEDG) trades at $30.52, down 3.05% on the day, as the stock faces bearish technical signals and ongoing financial challenges. The company reported a net loss of $405.45 million in 2025 despite revenue growth to $1.18 billion, with negative profit margins and declining cash flow trends. Recent news highlights multiple law firm investigations into investor claims, creating additional headwinds alongside sector-wide pressure from high borrowing costs affecting solar project financing.
The outlook remains challenging with bearish technical indicators and fundamental weaknesses, though analyst consensus suggests potential upside to $37.75. Key risks include ongoing financial losses, competitive pressures, and legal investigations, while opportunities exist in the company's AI data center initiatives and long-term revenue targets of $2.4 billion by 2029.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →